MX2021010221A - Poblaciones mejoradas de celulas germinales para terapia alogenica. - Google Patents

Poblaciones mejoradas de celulas germinales para terapia alogenica.

Info

Publication number
MX2021010221A
MX2021010221A MX2021010221A MX2021010221A MX2021010221A MX 2021010221 A MX2021010221 A MX 2021010221A MX 2021010221 A MX2021010221 A MX 2021010221A MX 2021010221 A MX2021010221 A MX 2021010221A MX 2021010221 A MX2021010221 A MX 2021010221A
Authority
MX
Mexico
Prior art keywords
stem cell
cell populations
improved stem
allogeneic
allogeneic therapy
Prior art date
Application number
MX2021010221A
Other languages
English (en)
Inventor
Valderas Alvaro Avivar
La Rosa Morales Olga De
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2021010221A publication Critical patent/MX2021010221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención se refiere a una población mejorada de células germinales para terapia alogénica con células germinales, en particular para el tratamiento de pacientes presensibilizados y para retratamiento. Además, se proporcionan métodos para obtener dichas poblaciones de células germinales. Además, la presente invención se refiere a composiciones farmacéuticas que comprenden dichas poblaciones de células germinales y su uso en terapia alogénica con células germinales.
MX2021010221A 2019-02-27 2020-02-26 Poblaciones mejoradas de celulas germinales para terapia alogenica. MX2021010221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382141 2019-02-27
PCT/EP2020/055017 WO2020174002A1 (en) 2019-02-27 2020-02-26 Improved stem cell populations for allogeneic therapy

Publications (1)

Publication Number Publication Date
MX2021010221A true MX2021010221A (es) 2021-09-21

Family

ID=65766951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010221A MX2021010221A (es) 2019-02-27 2020-02-26 Poblaciones mejoradas de celulas germinales para terapia alogenica.

Country Status (12)

Country Link
US (1) US20220202868A1 (es)
EP (1) EP3931307A1 (es)
JP (1) JP2022522187A (es)
KR (1) KR20210133988A (es)
CN (1) CN113544261A (es)
AU (1) AU2020228979A1 (es)
BR (1) BR112021016316A8 (es)
CA (1) CA3127851A1 (es)
IL (1) IL285837A (es)
MX (1) MX2021010221A (es)
SG (1) SG11202108114YA (es)
WO (1) WO2020174002A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
DE69922933T2 (de) * 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US7030292B2 (en) * 2001-01-02 2006-04-18 Stemron, Inc. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
JP2015500810A (ja) * 2011-11-30 2015-01-08 アドバンスド セル テクノロジー、インコーポレイテッド 間葉系間質細胞及びその関連用途
CN104487568B (zh) * 2012-07-11 2017-08-15 爱姆斯坦生物技术公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
EP2931877B1 (en) * 2012-12-14 2019-07-31 Rutgers, The State University of New Jersey Methods modulating immunoregulatory effect of stem cells
AU2014230014B2 (en) * 2013-03-15 2019-11-14 Tigenix, S.A.U. Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC)
EP3013943B1 (en) * 2013-06-25 2019-04-10 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
JP6811724B2 (ja) * 2015-04-24 2021-01-13 ティジェニクス エス．エー．ユー． 細胞療法に対する臨床応答を決定するためのバイオマーカー
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2017188403A1 (ja) * 2016-04-27 2017-11-02 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法

Also Published As

Publication number Publication date
AU2020228979A1 (en) 2021-09-23
SG11202108114YA (en) 2021-08-30
US20220202868A1 (en) 2022-06-30
CN113544261A (zh) 2021-10-22
IL285837A (en) 2021-10-31
JP2022522187A (ja) 2022-04-14
EP3931307A1 (en) 2022-01-05
KR20210133988A (ko) 2021-11-08
WO2020174002A1 (en) 2020-09-03
BR112021016316A2 (pt) 2021-10-26
BR112021016316A8 (pt) 2023-04-11
CA3127851A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2019001920A (es) Arn la terapia contra el cancer.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
NO20063716L (no) Anvendelse av lavdose erytropoietin ved stimulering av endotel forloperceller, regenerering av organer og sinking av progresjonen av sluttorganskader
MX2022004989A (es) Composiciones farmaceuticas de albumina y rapamicina.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
GEP20247585B (en) Furoindazole derivatives
MX2021000955A (es) Terapia de incremento mitocondrial para enfermedades mitocondriales primarias.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.